10º Foro de Inmunologia Traslacional en Inmmunoterapia del cáncer

21 10º FORO DE Inmunología Traslacional e INMUNOTERAPIA DEL CÁNCER 11:20-11:50 Coffee break. Poster session - Pausa café – Exhibición de pósteres Poster Session III Clinical experiences and biomarkers CP-20. ORAL SQUAMOUS CARCINOMA CELLS DIFFERENCIATE MONOCYTES INTO IMMUNOSUPPRESSIVE CD25+CD163+CD206+ MACROPHAGES Héctor F. Peláez-Prestel; Fernando González Martín; Esther María Lafuente Duarte; Pedro A. Reche Gallardo Department of Immunology, Universidad Complutense de Madrid, Madrid, Spain CP-21. METHYLATION SIGNATURE OF RESPONSE IN MELANOMA PATIENTS TREATED WITH IMMUNOTHERAPY Alberto Ríos Muñoz1,2; Andrea González-Hernández 1,2; Miguel-Ángel Berciano-Guerrero1; Jaime Dubbelman1,3; Beatriz Martínez-Gálvez1; Ángel Díaz-Lagares3; Isabel Barragán1; Elisabeth Pérez-Ruiz1 1Medical Oncology Service (Group of Translational Research in Cancer Immunotherapy and Epigenetics), Regional and Clinical University Hospitals, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain. 2Universidad de Málaga, Málaga, Spain. 3Epigenomics Unit, Cancer Epigenomics, Translational Medical Oncology Group (ONCOMET), Instituto de Investigación Sanitaria de Santiago (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela (CHUS, SERGAS), Santiago de Compostela, Spain CP-22. EXOSOMAL MICRORNAS AS IMMUNOTHERAPY BIOMARKERS: PREDICTING RESPONSE TO PEMBROLIZUMAB IN NON-SMALL CELL LUNG CANCER Alejandro Castillo Peña; Laura Boyero; Johana Benedetti; Miriam Alonso; Amparo SánchezGastaldo; José Francisco Noguera Uclés; Ana Salinas; M.ª Luisa Valdivia Ferreira; Reyes Bernabé Caro; Sonia Molina Pinelo Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain CP-23. CHANGES IN INTERFERON-RELATED CYTOKINES DURING PD-(L)1 INHIBITION THERAPY AND THEIR ASSOCIATION WITH IMMUNE-RELATED ADVERSE EVENTS Leticia Alserawan1,2; Maria Mulet2; Geòrgia Anguera3; Mariona Riudavets3,4; Carlos Zamora2; Rubén Osuna2; Jorgina Serra-López3; Andrés Barba Joaquín3; Ivana Sullivan3; Margarita Majem3*; Silvia Vidal2* 1Department of Immunology, Hospital Clínic de Barcelona, Barcelona, Spain. 2Department of Inflammatory Diseases, Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, Institut de Recerca Sant Pau (IIB Sant Pau), Barcelona, Spain. 3Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. 4Department of Pneumologie, Hôpital Cochin - APHP Centre, Paris, France *These authors contributed equally to this work.

RkJQdWJsaXNoZXIy MTQzMjMwMg==